FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002260284> ?p ?o ?g. }

• W2002260284 endingPage "B24" @default.
• W2002260284 startingPage "B24" @default.
• W2002260284 abstract "Introduction: Personalized medicine (PM) is a concept that has raised high expectations amongst scientists, clinicians, and patients. An emerging approach is to examine tumor biopsy material for genomic changes that are known targets of currently available therapeutic agents, with the assumption that a clinical benefit will be observed if the target is inhibited. While striking anecdotal reports are predictable from this approach, the clinical impact of these agents is limited by the inevitable development of therapeutic resistance. Our focus is on the design of parallel research programs using both in vitro and in vivo strategies, in an effort to delay or inhibit resistance. We present here preliminary data for a signature of resistance to standard first-line treatment - fluorouracil, folinic acid, oxaliplatin and bevacizumab (FOLFOX/B) using cell line models of resistance to this regimen. In parallel, we are conducting a prospective study to identify biomarkers of clinical resistance to first-line therapy in patients with metastatic colorectal cancer (CRC) (NCT00984048). Methods: Ten established CRC cell lines were treated with FOLFOX/B and categorized as resistant or sensitive based on IC50 values. In parallel, patients who consented to an initial biopsy and one at disease progression following an initial response were identified as intrinsically resistant or as having acquired resistance during treatment. CRC cell lines that were initially sensitive were rendered resistant to mimic the acquired resistance in patients, by serial passages with gradual increases in concentration of the combination regimen. We compared microarray data from three sensitive and three resistant cell lines. Results: We found a different expression pattern from microarray data comparing sensitive and resistant cell lines, thereby indicating a potential signature of resistance to FOLFOX/B. Interestingly, we found that the Src family kinase Lyn was overexpressed in resistant cells lines. Treating cells with non-cytotoxic concentration of dasatinib, a dual Src family kinase and Abl inhibitor, sensitized both the parental sensitive cells and the cells with acquired resistance to FOLFOX/B, thereby suggesting that combination treatment with dasatinib may be effective in delaying or inhibiting resistance. We have thus far collected needle core biopsies from liver metastases from forty patients who agreed to partake in this multi-center trial. Eligible patients have confirmed metastatic CRC, measurable disease, and consent to three needle-core biopsies (NCBs) of a non-resectable liver metastasis before treatment and at resistance, as well as serial blood collection throughout the study. Using standard operating procedures developed for this trial, we were able to both preserve morphology and obtain high-quality genomic material from biopsy tissue. We will determine if the resistance signature and overexpression of Lyn observed in the resistant CRC cell lines are similarly demonstrated in patients that were intrinsically resistant to FOLFOX/B. Conclusions: We have designed parallel in vitro and in vivo experiments to study resistance to standard first-line treatment for mCRC. These studies provide insight on metastatic signatures of resistance and suggest combination therapies to delay or inhibit therapeutic resistance in patients." @default.
• W2002260284 created "2016-06-24" @default.
• W2002260284 creator A5001700783 @default.
• W2002260284 creator A5002072156 @default.
• W2002260284 creator A5005764534 @default.
• W2002260284 creator A5009190068 @default.
• W2002260284 creator A5012005454 @default.
• W2002260284 creator A5018143555 @default.
• W2002260284 creator A5019526929 @default.
• W2002260284 creator A5023267102 @default.
• W2002260284 creator A5024490678 @default.
• W2002260284 creator A5028943358 @default.
• W2002260284 creator A5029097581 @default.
• W2002260284 creator A5031333036 @default.
• W2002260284 creator A5042063888 @default.
• W2002260284 creator A5048707534 @default.
• W2002260284 creator A5049481562 @default.
• W2002260284 creator A5051029434 @default.
• W2002260284 creator A5052864271 @default.
• W2002260284 creator A5055032546 @default.
• W2002260284 creator A5055280080 @default.
• W2002260284 creator A5056081721 @default.
• W2002260284 creator A5062137018 @default.
• W2002260284 creator A5068296807 @default.
• W2002260284 creator A5076716605 @default.
• W2002260284 creator A5079312035 @default.
• W2002260284 date "2012-05-15" @default.
• W2002260284 modified "2023-10-18" @default.
• W2002260284 title "Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors" @default.
• W2002260284 doi "https://doi.org/10.1158/1078-0432.mechres-b24" @default.
• W2002260284 hasPublicationYear "2012" @default.
• W2002260284 type Work @default.
• W2002260284 sameAs 2002260284 @default.
• W2002260284 citedByCount "0" @default.
• W2002260284 crossrefType "journal-article" @default.
• W2002260284 hasAuthorship W2002260284A5001700783 @default.
• W2002260284 hasAuthorship W2002260284A5002072156 @default.
• W2002260284 hasAuthorship W2002260284A5005764534 @default.
• W2002260284 hasAuthorship W2002260284A5009190068 @default.
• W2002260284 hasAuthorship W2002260284A5012005454 @default.
• W2002260284 hasAuthorship W2002260284A5018143555 @default.
• W2002260284 hasAuthorship W2002260284A5019526929 @default.
• W2002260284 hasAuthorship W2002260284A5023267102 @default.
• W2002260284 hasAuthorship W2002260284A5024490678 @default.
• W2002260284 hasAuthorship W2002260284A5028943358 @default.
• W2002260284 hasAuthorship W2002260284A5029097581 @default.
• W2002260284 hasAuthorship W2002260284A5031333036 @default.
• W2002260284 hasAuthorship W2002260284A5042063888 @default.
• W2002260284 hasAuthorship W2002260284A5048707534 @default.
• W2002260284 hasAuthorship W2002260284A5049481562 @default.
• W2002260284 hasAuthorship W2002260284A5051029434 @default.
• W2002260284 hasAuthorship W2002260284A5052864271 @default.
• W2002260284 hasAuthorship W2002260284A5055032546 @default.
• W2002260284 hasAuthorship W2002260284A5055280080 @default.
• W2002260284 hasAuthorship W2002260284A5056081721 @default.
• W2002260284 hasAuthorship W2002260284A5062137018 @default.
• W2002260284 hasAuthorship W2002260284A5068296807 @default.
• W2002260284 hasAuthorship W2002260284A5076716605 @default.
• W2002260284 hasAuthorship W2002260284A5079312035 @default.
• W2002260284 hasConcept C121608353 @default.
• W2002260284 hasConcept C126322002 @default.
• W2002260284 hasConcept C143998085 @default.
• W2002260284 hasConcept C502942594 @default.
• W2002260284 hasConcept C526805850 @default.
• W2002260284 hasConcept C54355233 @default.
• W2002260284 hasConcept C71924100 @default.
• W2002260284 hasConcept C81885089 @default.
• W2002260284 hasConcept C86803240 @default.
• W2002260284 hasConceptScore W2002260284C121608353 @default.
• W2002260284 hasConceptScore W2002260284C126322002 @default.
• W2002260284 hasConceptScore W2002260284C143998085 @default.
• W2002260284 hasConceptScore W2002260284C502942594 @default.
• W2002260284 hasConceptScore W2002260284C526805850 @default.
• W2002260284 hasConceptScore W2002260284C54355233 @default.
• W2002260284 hasConceptScore W2002260284C71924100 @default.
• W2002260284 hasConceptScore W2002260284C81885089 @default.
• W2002260284 hasConceptScore W2002260284C86803240 @default.
• W2002260284 hasIssue "10 Supplement" @default.
• W2002260284 hasLocation W20022602841 @default.
• W2002260284 hasOpenAccess W2002260284 @default.
• W2002260284 hasPrimaryLocation W20022602841 @default.
• W2002260284 hasRelatedWork W2075214100 @default.
• W2002260284 hasRelatedWork W2326463105 @default.
• W2002260284 hasRelatedWork W2364051953 @default.
• W2002260284 hasRelatedWork W2381416288 @default.
• W2002260284 hasRelatedWork W2388808113 @default.
• W2002260284 hasRelatedWork W2392730113 @default.
• W2002260284 hasRelatedWork W2418638721 @default.
• W2002260284 hasRelatedWork W2949011490 @default.
• W2002260284 hasRelatedWork W3004259476 @default.
• W2002260284 hasRelatedWork W4309211534 @default.
• W2002260284 hasVolume "18" @default.
• W2002260284 isParatext "false" @default.
• W2002260284 isRetracted "false" @default.
• W2002260284 magId "2002260284" @default.
• W2002260284 workType "article" @default.